Related Experiment Videos
Familial antithrombin III deficiency
Insights
Antithrombin III deficiency significantly increases the risk of venous thromboembolic disease. This study details three Scottish families with this deficiency, reviewing its characteristics and management.
Area of Science:
- Biochemistry
- Hematology
- Genetics
Background:
- Antithrombin III is a key inhibitor of blood coagulation.
- Deficiency in Antithrombin III leads to a high risk of venous thromboembolic disease.
- Understanding Antithrombin III's role is crucial for managing thrombotic disorders.
Purpose of the Study:
- To describe three Scottish families with Antithrombin III deficiency.
- To review existing literature on Antithrombin III deficiency.
- To discuss the molecular, clinical, and therapeutic aspects of Antithrombin III deficiency.
Main Methods:
- Clinical case descriptions of three families.
- Literature review of reported Antithrombin III deficiency cases.
- Analysis of Antithrombin III properties, function, and assay methods.
Main Results:
- Detailed characterization of Antithrombin III deficiency in three Scottish families.
- Compilation of molecular abnormalities, inheritance patterns, and clinical presentations.
- Review of diagnostic assays and therapeutic strategies.
Conclusions:
- Antithrombin III deficiency is a heritable condition predisposing to thrombosis.
- Comprehensive understanding aids in diagnosis and management.
- Antithrombotic drugs and Antithrombin III concentrates are therapeutic options.
Abstract:
Antithrombin III is the major physiological inhibitor of the coagulation mechanism and a deficiency of this protein results in a marked predisposition to venous thromboembolic disease. Three Scottish families with a deficiency of this protein are described and other reported families are reviewed. The properties, functions and methods of assay of antithrombin III are outlined; the molecular abnormalities, inheritance, clinical and laboratory characteristics of antithrombin III deficiency are described, and the use of antithrombotic drugs and human antithrombin III concentrates in this deficiency is discussed.